24 Hrs
Source:
المشهد العربي
Pfizer ups 2026 revenue forecast
Pfizer announced its financial results for the second quarter of 2026, surpassing expectations thanks to the growth in sales of major drugs not related to COVID-19, leading to an upward revision of the 2026 revenue forecast to a range between $60.5 billion and $62.5 billion. The company also reported a net loss of $4.3 billion due to accounting provisions and a decline in COVID-19 product sales. Operational revenues reached $15.03 billion, and adjusted earnings per share were $0.77. Negative adjustments were made to the forecasts of some experimental drugs, and the company announced the withdrawal of the "Oksbrereta" product.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)